N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1

• Main Authors: Gao, W. (Author), Li, T. (Author), Shi, J. (Author), Song, W. (Author), Xing, Y. (Author), Yang, L. (Author), Zhang, Z. (Author)
• Format: Article
• Language: English
• Published: Taylor and Francis Ltd. 2022
• Subjects: adenosine; Adenosine; Cell Line, Tumor; Gastric cancer; gene expression regulation; Gene Expression Regulation, Neoplastic; genetics; human; Humans; IGF2BP2; IGF2BP2 protein, human; messenger RNA; metabolism; N6-methyladenosine; N-methyladenosine; pathology; RNA binding protein; RNA, Messenger; RNA-Binding Proteins; SIRT1; SIRT1 protein, human; sirtuin 1; Sirtuin 1; Stomach Neoplasms; stomach tumor; tumor cell line
• Online Access: View Fulltext in Publisher

 N6-methyladenosine (m6A) modification acts as the most prevalent internal modification in eukaryotic mRNA. Emerging evidence shows the critical biological roles of m6A key enzymes in human cancers. However, the roles of m6A binding protein IGF2BP2 in gastric cancer (GC) progression are still unclear. In this study, we confirmed that IGF2BP2 was highly expressed in GC cell lines and tumor tissues. Knocking down of IGF2BP2 suppressed cell proliferation and migration, and repressed xenograft tumor growth in vivo, while IGF2BP2 overexpression promoted the proliferation and migration. Mechanistically, we identified that IGF2BP2 regulated GC the proliferation/migration through recognizing the m6A modification sites of SIRT1 mRNA. In general, our findings demonstrated a novel regulatory mechanism that IGF2BP2/SIRT1 axis modulated GC progression in an m6A-dependent manner, suggesting that m6A may be a therapeutic target for GC. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.